Bifogade filer
Q-linea participates in comparative rapid AST study
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Q-linea AB (publ) (OMX: QLINEA) – Q-linea today announces that the company will participate in a study comparing the benefits of three different rapid AST devices to current standard of care.
A total of 240 patients treated for Gram-negative septicemia will be enrolled in the study at a major European hospital. Septicemia is a bacterial infection that spreads into the bloodstream and sepsis can be the body's response to that infection. Positive blood culture samples will be analyzed using three rapid phenotypic AST systems. Diagnostic performance, workflow adaptability, and reduction in time to optimal antibiotic treatment for the three systems will be compared to the current standard of care method.
“We are delighted to announce the participation of Q-linea in this comparative study. Considering the breadth of the ASTar G- antibiotic panel and the speed of results, we believe that patients will derive major clinical benefits from its utilization," says Jonas Jarvius, CEO of Q-linea.